GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

TaiRx 6580.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

11.10

0.00%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About TaiRx

Its shares trade on Taipei Exchange under the ticker 6580.TWO. It has been listed since 20 June 2017. In the fiscal year to 31 December 2025, it reported revenue of TWD 27.9m and a net loss of TWD 221.1m. At that date it held total assets of TWD 465.2m and shareholders' equity of TWD 441.6m.

TaiRx, Inc. engages in the research and development of novel drug products for cancer treatment. The company is headquartered in Taipei City, Taipei. The company went IPO on 2017-06-20. The firm primarily focus on the research and development of cancer treatment drugs and sepsis adjuvant therapy drugs. The firm's main products include CVM-1118, Rexis, Zelnite, TRX-NOC, TRX-920, TRX-711, TRX-105 and others. CVM-1118 and Rexis are in clinical trials, and Zelnite drugs are sold to domestic medical institutions at all levels through distributors.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
20 Jun 2017
Website
trx.com.tw ↗

Leadership

Pay as last reported

  • Qun LinChairman of the Board, Chief Strategy Officer, since 2020
  • Mr. Jackson HuangChief Financial Officer
  • Mr. Du-Shieng ChienGeneral Manager, Director, since 2011
  • Ms. Yi-Wen ChuSenior Deputy General Manager, Director
  • Yutong HongChief Product Officer
  • Shengzhu GuoDirector
  • Tianshang WuDirector
  • Wenqi XuDirector
  • Yu-Kuan LinIndependent Director
  • Zhenwu ZhangIndependent Director
  • Zhongqiang ZhuIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • TaiRx Inc focuses on cancer treatment drug R&D with CVM-1118 and Rexis in clinical trials.
  • TaiRx Inc sells Zelnite drugs to domestic medical institutions through distributors in Taipei City.
  • TaiRx Inc's products include TRX-NOC, TRX-920, TRX-711, and TRX-105 for cancer treatment.

Weaknesses

  • TaiRx Inc's products are limited to cancer treatment and sepsis adjuvant therapy drugs.
  • TaiRx Inc's clinical trial drugs CVM-1118 and Rexis have not yet reached market approval.
  • TaiRx Inc relies on domestic medical institutions for Zelnite drug sales in Taipei City.

Opportunities

  • TaiRx Inc can expand its cancer treatment drug portfolio with TRX-NOC and TRX-920 in development.
  • TaiRx Inc can leverage its domestic medical institution network for Zelnite drug sales growth.
  • TaiRx Inc can pursue international markets for its cancer treatment drugs after clinical trials.

Threats

  • TaiRx Inc faces competition from other biotechnology firms in the Health Care sector.
  • TaiRx Inc's clinical trials for CVM-1118 and Rexis may face regulatory delays in Taipei City.
  • TaiRx Inc's sepsis adjuvant therapy drugs may face market saturation in the domestic market.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.